Aclaris Therapeutics, Inc. Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2022. The filing is an annual report, not a standalone fourth-quarter filing. Aclaris is a clinical-stage biopharmaceutical company developing immuno-inflammatory drug candidates and pursuing licensing and other strategic partnerships. It also operates a contract research services business.
Business Context and Pipeline
- Zunsemetinib: Oral MK2 inhibitor in Phase 2b rheumatoid arthritis and Phase 2a hidradenitis suppurativa and psoriatic arthritis programs.
- ATI-1777: Topical “soft” JAK1/3 inhibitor in a Phase 2b atopic dermatitis trial.
- ATI-2138: Oral ITK/JAK3 inhibitor; Phase 1 multiple-ascending-dose trial began in December 2022, with ulcerative colitis identified as the initial development target.
- ATI-2231: Preclinical oral MK2 inhibitor being explored for pancreatic and metastatic breast cancer and prevention of metastatic breast cancer-related bone loss.
- Aclaris has no manufacturing facilities and relies on third parties for preclinical and clinical drug supply.
Financial and Liquidity Metrics
| Metric | 2022 | 2021 | Change |
|---|---|---|---|
| Total revenue | $29.8 million | $6.8 million | +$23.0 million |
| Contract research revenue | $4.4 million | $5.8 million | -$1.4 million |
| Licensing revenue | $25.1 million | $0.8 million | +$24.3 million |
| Research and development expense | $77.8 million | $43.8 million | +$34.0 million |
| General and administrative expense | $25.1 million | $23.6 million | +$1.5 million |
| Loss from operations | $(89.9) million | $(89.7) million | $(0.1) million |
| Net loss | $(86.9) million | $(90.9) million | +$4.0 million |
| Net loss per share | $(1.33) | $(1.60) | Improved |
| Net cash used in operating activities | $(67.6) million | $(52.1) million | Higher use |
| Cash, cash equivalents and marketable securities | $229.8 million | $225.7 million | +$4.1 million |
At December 31, 2022, cash and cash equivalents were $45.3 million and marketable securities were $184.5 million. Stockholders’ equity was $197.6 million, total liabilities were $57.0 million, and the contingent consideration liability was $33.1 million. The company had no outstanding debt following repayment of its Silicon Valley Bank loan in July 2021. Remaining lease liabilities were $2.3 million, with aggregate remaining lease payment obligations of approximately $2.9 million.
Cash flow from investing activities was positive $12.6 million, primarily because proceeds from sales and maturities of marketable securities exceeded purchases. Financing activities provided $72.9 million, principally from the April 2022 at-the-market offering. Aclaris sold 4.84 million shares for $75.0 million of gross proceeds and $72.7 million of net proceeds.
Material Changes Versus 2021
- Revenue increased substantially because of $17.6 million received from Eli Lilly under a patent license agreement and a $5.0 million upfront payment from Pediatrix for ATI-1777 rights in Greater China. Licensing revenue also included approximately $1.0 million of RHOFADE royalties.
- Research and development expense increased 78%, reflecting expanded clinical development of zunsemetinib, ATI-1777 and ATI-2138, as well as continued development of ATI-2231 and discovery programs.
- Contract research revenue declined because fewer laboratory hours were billed as the company increased its focus on internal development programs.
- The revaluation charge for contingent consideration declined to $4.7 million from $24.3 million, although the liability increased to $33.1 million from $28.4 million.
- Net loss improved modestly despite substantially higher research and development spending, supported by licensing revenue and higher interest income.
- Shares outstanding increased to 66.7 million at year-end from 61.2 million, primarily due to the 2022 at-the-market equity sale and equity awards.
Guidance, Outlook, Risks and Unusual Items
- Management expects topline data from the hidradenitis suppurativa trial in March 2023, ATI-1777 Phase 2b in mid-2023, rheumatoid arthritis Phase 2b in the second half of 2023, ATI-2138 Phase 1 MAD in the second half of 2023, and psoriatic arthritis Phase 2a by the end of 2023.
- Clinical development activities for ATI-2231 were expected to begin in 2023, potentially in collaboration with an academic third party.
- The company expects continued operating losses and requires additional capital to complete clinical development and support preclinical and discovery activities. Management believes existing liquidity will fund operations and capital requirements for more than 12 months from the financial statement issuance date, but this depends on current operating assumptions.
- Potential future funding may come from equity or debt offerings, licensing transactions, partnerships or other strategic transactions. Additional equity financing could dilute existing stockholders.
- The largest financial judgment is the fair value of contingent consideration related primarily to zunsemetinib. The valuation uses Level 3 assumptions, including development and regulatory success probabilities of 10% to 40%, projected sales and discount rates of approximately 9.8% to 10.2%.
- The company remains dependent on successful clinical trials, regulatory approvals, strategic partners, third-party manufacturers and adequate reimbursement. Competition from established pharmaceutical companies and other JAK and immuno-inflammatory therapies is substantial.
- Other risks include clinical enrollment or safety delays, regulatory failure, intellectual-property challenges, manufacturing and supply interruptions, macroeconomic conditions, inflation, rising interest rates, COVID-19 effects, cybersecurity incidents and potential future equity dilution.
- The company reported no material pending legal proceedings. A securities class-action settlement of approximately $2.7 million was paid in January 2022 and was within insurance coverage.
- Management and the independent auditor concluded that internal control over financial reporting was effective as of December 31, 2022.
Important Facts for Investors to Verify
- Whether reported 2023 clinical topline milestones were achieved on schedule and whether results support advancement into later-stage trials.
- The durability and safety of zunsemetinib, ATI-1777 and ATI-2138 clinical results, including any emerging cardiovascular, laboratory or other adverse-event signals.
- The remaining cash runway under updated spending assumptions and the timing and terms of any future financing.
- The status and economics of the Lilly, Pediatrix, EPI Health and Confluence-related milestone, royalty and payment obligations.
- Changes in the $33.1 million contingent consideration liability and the sensitivity of that valuation to development probabilities and projected sales.
- Third-party manufacturing capacity, supply redundancy and compliance with current good manufacturing practices.
- The scope, enforceability and remaining term of patents covering the lead drug candidates.
- Potential dilution from equity offerings, stock options and restricted stock units; the filing reported 6.7 million potential shares excluded from diluted loss-per-share calculations.